

SUB
C1
C04
A1
C04

5. (Amended) An isolated polynucleotide encoding a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising SEQ ID NO:307 or a complement of said sequence.

6. (Amended) An isolated polynucleotide, comprising a sequence of SEQ ID NO:307.

A2

16. (Amended) An isolated polynucleotide encoding a fusion protein comprising at least one polypeptide encoded by SEQ ID NO:308.

A3
SUB
C2

60. (Amended) A diagnostic kit, comprising:
(a) a polynucleotide according to claim 4; and
(b) a diagnostic reagent for use in a polymerase chain reaction or hybridization assay.


REMARKS

In reply to the Restriction Requirement dated August 15, 2001, applicants have elected Group I, claims 4-7, 16, and 58-60, and SEQ ID NO: 307. By this amendment, claims 7, 58, and 59 have been canceled and claims 4, 5, 6, 16 and 60 have been amended.

Consideration of the elected claims is now respectfully requested. The Examiner is invited to contact the undersigned with any questions, comments, and/or suggestions relating to this matter. On the basis of the above amendments, applicants believe that the Application is in order for allowance.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC


Jeffrey Hundley
Registration No. 42,676

JEH:sds

Enclosure:

Postcard

Check

Petition for an Extension of Time

701 Fifth Avenue, Suite 6300

Seattle, Washington 98104-7092

Phone: (206) 622-4900/Fax: (206) 682-6031

D:\NIPort\NIPort\Manage\SHARONS\131373_1.DOC